Petróleo Brasileiro SA vs ResMed Inc. — how do they compare? Petróleo Brasileiro SA trades at $18.93 (market cap $112.59B), while ResMed Inc. trades at $193.21 (market cap $28.40B). The key difference: Petróleo Brasileiro SA is far larger — about 4× ResMed Inc.'s market cap, and Petróleo Brasileiro SA pays the higher dividend (9.51%). Which is the better fit depends on your goals.
| PBR | RMD | |
|---|---|---|
Market Cap | $112.59B | $28.40B |
Sector | Technology | Health |
52-Week High | $22.03 | $293.73 |
52-Week Low | $11.54 | $182.82 |
Enterprise Value | $176.05B | $27.58B |
Dividend Yield | 9.51% | 1.23% |
Signals from Pluang's Aura AI — not financial advice
PBR trades at $18.19, up 1.22% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a low P/E of 5.73 and robust profitability, including a 21.47% net income margin. Recent news highlights expansion in deepwater operations and strategic partnerships, while earnings have mostly beaten expectations except for a Q1 2026 miss.
The outlook is positive, supported by attractive valuation, solid cash flows, and dividend payments. Risks include oil price volatility and execution of new projects. Analyst consensus leans bullish with 50% buy ratings, but overbought RSI levels suggest near-term caution.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →